IART Integra Lifesciences Holdings Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IART

Price (delayed)

$31.45

Market cap

$2.48B

P/E Ratio

61.67

Dividend/share

N/A

EPS

$0.51

Enterprise value

$3.93B

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra ...

Highlights
IART's quick ratio has soared by 62% from the previous quarter and by 50% YoY
Integra Lifesciences Holdings's net income has plunged by 77% YoY and by 41% from the previous quarter
IART's EPS has dropped by 75% year-on-year and by 40% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.integralife.com
Peers: SYK TFX XRAY CNMD

Key stats

What are the main financial stats of IART
Market
Shares outstanding
78.8M
Market cap
$2.48B
Enterprise value
$3.93B
Valuations
Price to earnings (P/E)
61.67
Price to book (P/B)
1.54
Price to sales (P/S)
1.6
EV/EBIT
39.7
EV/EBITDA
17.62
EV/Sales
2.57
Earnings
Revenue
$1.53B
EBIT
$98.96M
EBITDA
$222.98M
Free cash flow
$60.93M
Per share
EPS
$0.51
Free cash flow per share
$0.78
Book value per share
$20.43
Revenue per share
$19.68
TBVPS
$25.93
Balance sheet
Total assets
$4.08B
Total liabilities
$2.48B
Debt
$2.04B
Equity
$1.6B
Working capital
$1.11B
Liquidity
Debt to equity
1.28
Current ratio
4.68
Quick ratio
2.99
Net debt/EBITDA
6.51
Margins
EBITDA margin
14.6%
Gross margin
56.1%
Net margin
2.6%
Operating margin
5.2%
Efficiency
Return on assets
1%
Return on equity
2.5%
Return on invested capital
3.5%
Return on capital employed
2.6%
Return on sales
6.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IART stock price

How has the Integra Lifesciences Holdings stock price performed over time
Intraday
-0.25%
1 week
0.35%
1 month
10.08%
1 year
-30.95%
YTD
-27.78%
QTD
7.93%

Financial performance

How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.53B
Gross profit
$858.7M
Operating income
$79.11M
Net income
$40.23M
Gross margin
56.1%
Net margin
2.6%
Integra Lifesciences Holdings's net income has plunged by 77% YoY and by 41% from the previous quarter
The net margin has dropped by 76% year-on-year and by 41% since the previous quarter
IART's operating margin has dropped by 65% year-on-year and by 28% since the previous quarter
The operating income has dropped by 65% year-on-year and by 29% since the previous quarter

Growth

What is Integra Lifesciences Holdings's growth rate over time

Valuation

What is Integra Lifesciences Holdings stock price valuation
IART P/E details
P/E
61.67
P/B
1.54
P/S
1.6
EV/EBIT
39.7
EV/EBITDA
17.62
EV/Sales
2.57
IART's EPS has dropped by 75% year-on-year and by 40% since the previous quarter
The stock's price to earnings (P/E) is 39% more than its last 4 quarters average of 44.4 and 28% more than its 5-year quarterly average of 48.4
The P/B is 47% lower than the 5-year quarterly average of 2.9 and 23% lower than the last 4 quarters average of 2.0
The equity has declined by 4.6% year-on-year
The price to sales (P/S) is 47% less than the 5-year quarterly average of 3.0 and 20% less than the last 4 quarters average of 2.0
The revenue has declined by 2.1% year-on-year

Efficiency

How efficient is Integra Lifesciences Holdings business performance
IART's ROA has shrunk by 78% YoY and by 44% QoQ
Integra Lifesciences Holdings's return on equity has shrunk by 75% YoY and by 40% QoQ
IART's return on invested capital has dropped by 64% year-on-year and by 30% since the previous quarter
IART's return on sales has dropped by 60% year-on-year and by 24% since the previous quarter

Dividends

What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IART.

Financial health

How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 64% higher than its total liabilities
IART's quick ratio has soared by 62% from the previous quarter and by 50% YoY
The current ratio has grown by 36% since the previous quarter and by 28% year-on-year
The debt is 28% greater than the equity
Integra Lifesciences Holdings's debt to equity has increased by 33% YoY and by 21% QoQ
The debt is up by 27% year-on-year and by 21% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.